Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230812582> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4230812582 abstract "Abstract Background: Non-Hodgkin's lymphoma is the seventh most common cancer in clinic. Lymphoma could be treated with newly developed anti-apoptotic small molecule inhibitors of bcl-2 such as ABT-199 or venetoclax. However most small molecules present numerous side effects and cancer becomes resistance to them rapidly. PNT100 is a DNA-based bcl-2 inhibitor that has shown great efficacy and safety in treating non-Hodgkin's lymphoma tumors. However, liposomal carrier(smarticles) that was used to deliver PNT100 eventually failed to produce robust efficacy in the latest clinical trial conducted by ProNai Therapeutics (now called Sierra Technology). The high cost of liposomal carriers, makes this targeted drug less affordable. In addition, the liposomal components may also present some minor side effects as reported in pilot phase II trial [17-22]. In this study, we eliminated liposome and used a specific Epigenic modification to deliver this 24bp oligonucleotides (PNT100) without using additional chemicals and named it Bicelin. Methods: In this study, the safety of Bicelin was determined by evaluating the cytopenia, nephrotoxicity and hepatotoxicity effects of this drug in healthy animal model (Rats). The rats in experimental group were received Bicelin (20 mg/kg/day) for 5 days a week. The treatment was continued for 3 consecutive weeks. The blood and urine samples were collected for evaluation and the rats were then sacrificed. The kidneys and liver tissues were fixed in formalin 10% to perform histological investigation using H&E staining. Results: The in vitro and in vivo results clearly demonstrate that Bicelin is target specific and highly safe. We observed no cytopenia when blood tests were performed after 15 consecutive injection of Bicelin; Urine analysis revealed no significant differences between experimental and control group and there was no nephrotoxicity or hepatotoxicity when kidney and liver tissues were examined. Conclusion: based on our in vitro and in vivo safety studies, our bcl2 inhibitor, Bicelin is much safer and about 10-fold more effective than its liposomal form (PNT2258). Considering preclinical, phase I and II studies of PNT2258, Bicelin is expected to be very safe and effective in clinic." @default.
- W4230812582 created "2022-05-11" @default.
- W4230812582 creator A5002557359 @default.
- W4230812582 creator A5014509675 @default.
- W4230812582 creator A5029984343 @default.
- W4230812582 creator A5047431349 @default.
- W4230812582 creator A5059915468 @default.
- W4230812582 creator A5078268749 @default.
- W4230812582 date "2020-10-30" @default.
- W4230812582 modified "2023-09-28" @default.
- W4230812582 title "Bicelin (B-cell lymphoma 2 inhibitor) a Highly Safe DNA-based Anti-cancer Drug Showed No in vivo Cytopenia, Nephrotoxicity and/or Hepatotoxicity" @default.
- W4230812582 doi "https://doi.org/10.21203/rs.3.rs-97298/v1" @default.
- W4230812582 hasPublicationYear "2020" @default.
- W4230812582 type Work @default.
- W4230812582 citedByCount "0" @default.
- W4230812582 crossrefType "posted-content" @default.
- W4230812582 hasAuthorship W4230812582A5002557359 @default.
- W4230812582 hasAuthorship W4230812582A5014509675 @default.
- W4230812582 hasAuthorship W4230812582A5029984343 @default.
- W4230812582 hasAuthorship W4230812582A5047431349 @default.
- W4230812582 hasAuthorship W4230812582A5059915468 @default.
- W4230812582 hasAuthorship W4230812582A5078268749 @default.
- W4230812582 hasBestOaLocation W42308125821 @default.
- W4230812582 hasConcept C121608353 @default.
- W4230812582 hasConcept C126189478 @default.
- W4230812582 hasConcept C126322002 @default.
- W4230812582 hasConcept C150903083 @default.
- W4230812582 hasConcept C207001950 @default.
- W4230812582 hasConcept C2776694085 @default.
- W4230812582 hasConcept C2779338263 @default.
- W4230812582 hasConcept C2780007613 @default.
- W4230812582 hasConcept C2780035454 @default.
- W4230812582 hasConcept C2780366003 @default.
- W4230812582 hasConcept C29730261 @default.
- W4230812582 hasConcept C502942594 @default.
- W4230812582 hasConcept C71924100 @default.
- W4230812582 hasConcept C86803240 @default.
- W4230812582 hasConcept C98274493 @default.
- W4230812582 hasConceptScore W4230812582C121608353 @default.
- W4230812582 hasConceptScore W4230812582C126189478 @default.
- W4230812582 hasConceptScore W4230812582C126322002 @default.
- W4230812582 hasConceptScore W4230812582C150903083 @default.
- W4230812582 hasConceptScore W4230812582C207001950 @default.
- W4230812582 hasConceptScore W4230812582C2776694085 @default.
- W4230812582 hasConceptScore W4230812582C2779338263 @default.
- W4230812582 hasConceptScore W4230812582C2780007613 @default.
- W4230812582 hasConceptScore W4230812582C2780035454 @default.
- W4230812582 hasConceptScore W4230812582C2780366003 @default.
- W4230812582 hasConceptScore W4230812582C29730261 @default.
- W4230812582 hasConceptScore W4230812582C502942594 @default.
- W4230812582 hasConceptScore W4230812582C71924100 @default.
- W4230812582 hasConceptScore W4230812582C86803240 @default.
- W4230812582 hasConceptScore W4230812582C98274493 @default.
- W4230812582 hasLocation W42308125821 @default.
- W4230812582 hasLocation W42308125822 @default.
- W4230812582 hasOpenAccess W4230812582 @default.
- W4230812582 hasPrimaryLocation W42308125821 @default.
- W4230812582 hasRelatedWork W12041411 @default.
- W4230812582 hasRelatedWork W13365833 @default.
- W4230812582 hasRelatedWork W13950329 @default.
- W4230812582 hasRelatedWork W17505737 @default.
- W4230812582 hasRelatedWork W17969427 @default.
- W4230812582 hasRelatedWork W19033831 @default.
- W4230812582 hasRelatedWork W20763325 @default.
- W4230812582 hasRelatedWork W4186716 @default.
- W4230812582 hasRelatedWork W5083821 @default.
- W4230812582 hasRelatedWork W5652719 @default.
- W4230812582 isParatext "false" @default.
- W4230812582 isRetracted "false" @default.
- W4230812582 workType "article" @default.